ClinicalTrials.gg
Enrolling by invitationNCT07234851Updated Dec 11, 2025

Understanding Mechanisms of Synaptic Degeneration Underlying Clinical Symptoms in Patients With MDs and NDs.

An observational study in Schizophrenia Disorder, Frontotemporal Dementia, Behavioral Variant and Major Depressive Disorder (MDD), sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Enrolling by invitation at 1 site in Spain. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
150
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 156 studies in Schizophrenia with a site in Spain — 12 open to participants now, 14 under way, 2 of them phase 3. Schizophrenia · Spain.

Planned enrollment
19th of 32
150 · median 200
Started
2025
with 1 other
Observational
32 of 156
4 open now
Primary completion
2029-06
later than 11 of 13 live
Registered
147th of 156
by date
Lead sponsor
5 of 156
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Among the 156 studies in Schizophrenia with a site in Spain, this one is the 19th largest by planned enrollment of the 32 observational ones that give a count, is one of 2 that started in 2025, is one of 32 observational ones, reaches primary completion later than 11 of the 13 other live ones, and was the 147th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

12 of the 156 studies in Schizophrenia with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 156 studies in Schizophrenia with a site in Spain, or all of them as a file.
02

Study summary

Clinical Study A. Retrospective Neuropathological Study of Synapse dysfunction.

This is a cross-sectional study of patients retrospectively collected from existing postmortem collections and from existing collections of iPSC-derived neurons. Postmortem tissue and iPSC-derived neurons from age and sex-matched unaffected volunteers without a MD or ND diagnosis are used as controls.

Read the detailed description

This study will:

  1. perform RNA sequencing of postmortem synapses from the prefrontal cortex of patients with schizophrenia or frontotemporal dementia and unaffected controls. The data will be combined with already available RNA sequencing data from established iPSC clones from schizophrenia or behavioural variant frontotemporal dementia patients and unaffected controls. The postmortem frontotemporal dementia samples have already been characterised in terms of frontal cortex pathology in a previous study and data from RNA sequencing of homogenates is available for comparison. The prefrontal cortex has been implicated as a core affected region across MDs and NDs making this the perfect region to determine common molecular drivers of synapse dysfunction. Pathway analysis of the RNA sequencing dataset will be performed to identify biological pathways or individual genes that are deregulated in the postmortem samples and iPSC lines from each condition. A total of 3 genes that converge between the postmortem and iPSC datasets will be selected for gene-editing. Each gene will be CRISPR/Cas9-repaired in 1 selected schizophrenia parental line and 1 selected frontotemporal dementia parental line. The impact of the induced transcriptional changes on functional and synaptic morphology phenotypes in neuronal cultures from each gene-edited line will be compared to the respective parental line and to lines from 3 healthy controls. A rescue of the disease phenotypes is expected such that the repaired edited line shows activity and synaptic morphology comparable to the healthy control lines and distinct from the unedited parental line. All experiments will include 3 biological replicates taking the total number of analyses to 420. The study will also determine the role of microglia on neuronal deficits in iPSC-derived neurons from the 20 available clones from patients with schizophrenia or behavioural variant frontotemporal dementia by comparing electrophysiological activity and synapse morphology in iPSC-derived neurons culture alone to those observed in iPSC-derived neurons co-cultured with iPSC-derived microglia differentiated from the same clones.
  2. compare the molecular composition of postmortem synapses from the prefrontal cortex across 3 MDs (major depressive disorder, bipolar disorder and schizophrenia) and identify differentially expressed proteins and dysfunctional protein networks through pathway analyses. To determine the potential effects of psychotropic drugs on synaptic proteomes, the study will quantify the concentrations of >200 psychoactive drugs and metabolites in both blood and cerebellum postmortem samples from the same donors and determine the correlation with the differentially expressed proteins. While blood analyses provide information on drugs present at the time of death, toxicological data in brain tissue, which accumulates drugs for weeks or even months after the last intake, serves as a better indicator of subjects' adherence to the treatments. Groups larger than 15 subjects are recommended for proteomic studies such as this. Each subject was paired to a control subject, matching sex, age, and postmortem interval and with no evidence of psychiatric or neurological conditions, according to their medical records.
  3. quantify and compare synapse loss in brain regions shown to be associated with reduced volumes in MD and ND patients postmortem. Specifically, the study will compare synapse density in the prefrontal cortex, hippocampus and striatum from patients with major depressive disorder, bipolar disorder, schizophrenia, Alzheimer's disease, frontotemporal dementia to age and sex-matched unaffected controls.
03

Conditions studied

  • Schizophrenia Disorder
  • Frontotemporal Dementia, Behavioral Variant
  • Major Depressive Disorder (MDD)
  • Bipolar Disorder (BD)
  • Alzheimer's Disease

Keywords

  • synapse
  • biomarker
  • induced pluripotent stem cells
  • mental disorder
  • neurodegenerative disorder
  • biofluids
  • psychiatric symptoms
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Resource 1. Frozen samples and paraffin sections from necropsy tissue will be provided by the University of Basque Country, Bilbao. Autopsies are performed in the Basque Institute of Legal Medicine, Bilbao, Spain.

Resource 2. Frozen samples and paraffin sections from necropsy tissue are recruited from the neurological tissue bank collection (IDIBAPS, Barcelona).

Resource 3. A collection of human induced pluripotent stem cell clones from clinically and genetically well-phenotyped schizophrenia (Natural and Medical Sciences Institute), behavioural variant frontotemporal dementia patients (University of Eastern Finland) and unaffected controls (both sites) that have already been functionally characterised in previous studies.

Eligibility criteria

Inclusion criteria for psychiatric disorders:

  • Age group: Midlife brain donors (age-at-death>40).
  • Sex distribution: % Female in schizophrenia (23%), major depressive disorder and controls (40%), bipolar disorder and controls (55%). These percentages match those typically found in these disorders.
  • Antemortem diagnosis of schizophrenia (paranoid-subtype diagnoses only to minimise the impact of potential confounding factors on the results and ensure homogeneity across schizophrenia subjects), major depression or bipolar disorder. Diagnoses are confirrmed antemortem by a psychiatrist using , fourth edition (DSM-IV) criteria, as recorded in the deceased individuals' medical records.

Exclusion criteria for psychiatric disorders:

For schizophrenia, cases displaying additional neurological or psychiatric conditions, such as histories of substance use disorder will be excluded. Postmortem delay >24h (to minimise perimortem confounding variables potentially affecting tissue quality.

Inclusion criteria for Neurodegenerative diseases:

  • Age group: Latelife brain donors (age-at-death>50).
  • Sex distribution: Alzheimer's disease (60%), frontotemporal dementia (65%). These percentages match those typically found in these diseases.
  • Neuropathological confirmation of Alzheimer's disease or frontotemporal lobar degeneration (C9orf72 repeat expansion carrier)Alzheimer's disease

Exclusion criteria for Neurodegenerative diseases:

Postmortem delay >24h (to minimise perimortem confounding variables potentially affecting tissue quality.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Major depressive disorder

    Cases that arrive to autopsy with a previous clinical diagnosis of major depressive disorder

  • Schizophrenia

    Cases that arrive to autopsy with a previous clinical diagnosis of schizophrenia or iPSC clones derived from a patient with a previous clinical diagnosis of schizophrenia

  • Bipolar disorder

    Cases that arrive to autopsy with a previous clinical diagnosis of major depressive disorder

  • Control

    Cases that arrived to autopsy without a prior diagnosis of a neurodegenerative or psychiatric condition or iPSC clones derived from a cognitively unimpaired healthy volunteer

  • Alzheimer's disease

    Cases that arrive to autopsy with neuropathological confirmation of Alzheimer's disease

  • frontotemporal dementia

    Cases that arrive to autopsy with neuropathological confirmation of frontotemporal lobar degeneration

06

What researchers measure

Primary outcomes

  1. Synaptic gene dysregulation in schizophrenia and frontotemporal dementia

    A list of genes that are differentially expressed in schizophrenia and frontotemporal dementia compared to controls identified by RNA sequencing a) synaptic fractions isolated from postmortem tissue from the prefrontal cortex of autopsy cases with a clinical diagnosis of schizophrenia or confirmation of frontotemporal lobar degeneration and b) established iPSC clones from patients with a clinical diagnosis of schizophrenia or behavioural variant frontotemporal dementia.

    Time frame: January 2025 to December 2029

  2. Molecular pathways related to synapse dysfunction in major depressive disorder, bipolar disorder and schizophrenia

    A list of biological processes that are enriched for proteins that are differentially expressed in major depressive disorder, bipolar disorder and schizophrenia compared to controls identified by proteomic analysis of synaptic fractions isolated from postmortem tissue from the prefrontal cortex of autopsy cases with a clinical diagnosis ofmajor depressive disorder, bipolar disorder or schizophrenia

    Time frame: January 2025 to December 2029

  3. Impact of psychiatric and neurodegenerative disorders on synapse density in affected brain regions.

    Density of immunoreactive objects labelled with an antibody to pre and post synapse markers (vGlut1, PSD-95) in the prefrontal cortex, hippocampus and striatum from autopsy cases with a prior diagnosis of major depressive disorder, bipolar disorder, schizophrenia and unaffected controls and brain donors with neuropathological confirmation of Alzheimer's disease or frontotemporal dementia and unaffected controls.

    Time frame: January 2028 to December 2029

Secondary outcomes

  1. Effects of psychotropic drugs on molecular pathways at the synapse related to major depressive disorder, schizophrenia and bipolar disorder

    A list of proteins that correlate with the concentrations of \>200 psychoactive drugs and metabolites in both blood and cerebellum from autopsy cases with a prior diagnosis of major depressive disorder, schizophrenia or bipolar disorder

    Time frame: July 2025 to December 2027

07

Study locations

1 site
  • Research Institute Sant Pau
    Barcelona, 08025, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Pseudoanonymised age, biological sex, ethnicity, country of origin/residence, diagnosis, age-at-death, postmortem interval, suicide attempts, comorbidities, therapies, toxicology, synapse density, transcriptome, proteome will uploaded to Zenodo (or ProteomeXchange Consortium PRIDE repository for genomic and proteomic data), which use DOIs as persistent and unique identifiers

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Jan2025-Jan2035

Access criteria: clinical and research communities

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jun 2029, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Nov 19, 2025
StartActual
Feb 1, 2025
Primary completionEst.
Jun 30, 2029
CompletionEst.
Sep 30, 2029
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07234851
Collaborators
University of Eastern Finland, University of the Basque Country (UPV/EHU), Natural and Medical Sciences Institute (NMI)
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Feb 1, 2025
Primary completion
Jun 30, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Dec 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion